TB/Flu-06E
The vaccine platform is based on the live influenza virus vector that is highly attenuated through alteration in NS1 protein function. This effect is achieved by the replacement of immunosuppressive C-terminal part of NS1 open reading frame with foreign sequences, encoding ESAT-6 antigen of M. tuberculosis. Importantly, viral vector itself acts as an adjuvant, stimulating…
Read Moremc2-CMX
The mc2-CMX vaccine is a live attenuated vaccine that was developed using M. tuberculosis Ag85, MPT-51 and HSP-x to generate a fusion protein called CMX. The nucleotide sequences corresponding to epitopes 85 to 159 bp of Ag85C and 91 to 112 bp of MPT51 and HSP-x. The gene sequence was inserted in the genome of…
Read MoreALHA
Ag85A-LpqH (AL) is a recombinant subunit vaccine that combines the T cell-stimulating antigen Ag85A with the humoral immunity-targeting antigen LpqH. It is constructed using the pET-21a(+) vector, expressed in E. coli BL21(DE3), and formulated with aluminum for subcutaneous administration.
Read MoreREA
A multifusion protein-based vaccine formulated with MPL/DDA.
Read MoreAd5-105K
The Inhaled Tuberculosis Vaccine (Adenovirus Type 5 Vector) developed by CanSino Biologics Inc. is a non-replicating viral-vectored vaccine intended for administration via nebulized inhalation by mouth. It is designed to induce both local mucosal immunity in the respiratory tract and systemic immune responses against Mycobacterium tuberculosis (Mtb). The adenovirus type 5 (Ad5) backbone functions as…
Read More